Scholarlink

Background <p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory condition, often treated with oral corticosteroids (OCS). OCS overexposure can increase the risk of adverse effects, highlighting the need for better treatment strategies including timely biologic therapy use. This study explored OCS use patterns in patients with severe CRSwNP in Canada pre-biologic initiation.</p> Methods <p>This retrospective, real-world study used IQVIA’s Private Drug Plan (PDP) claims database to examine OCS use patterns 0–24&#xa0;months pre-initiation of biologic therapy in patients with inferred CRSwNP in Canada (<i>n</i> = 747). Outcomes included OCS use patterns (proportions, claims per patient and by prescribing physician specialty, overexposure [≥ 1000&#xa0;mg annually, prednisone-equivalent]), demographics, and stratified by comorbid asthma.</p> Results <p>Of 747 patients indexed from the PDP, 81.0% had ≥ 1 OCS claim(s), with a median (interquartile range [IQR]) of 3.0 (4.0) claims per patient. Median (IQR) total OCS dose over 24&#xa0;months was 1020 (1420) mg; 41.5% of patients experienced OCS overexposure. OCS was primarily prescribed by general practitioners (35.9%) and otolaryngologists (32.8%). Patients had a median (IQR) age of 51 (18) years at index, 52.1% were male, and most were from Ontario (48.7%). OCS use was highest in patients with comorbid severe asthma.</p> Conclusions <p>This study highlights OCS overexposure in patients with CRSwNP pre-biologic initiation. Enhancing physician and patient awareness of appropriate OCS use and timely biologic initiation could reduce the risk of OCS-related adverse effects and improve CRSwNP management, benefiting long-term patient outcomes through shared decision-making.</p> <p><i>Trial registration</i> GSK study number 221872.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oral corticosteroid overexposure: characterizing oral corticosteroid use in patients with chronic rhinosinusitis with nasal polypS in Canada (ACTIONS) results

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月4日

查看全文
  • Yvonne Chan,
  • Marie-Noëlle Corriveau,
  • Jeffrey Beach,
  • Jenna Reynolds,
  • Koyo Usuba,
  • Danya Thayaparan,
  • Ali Tehrani,
  • Juejing Ling,
  • Huijuan Yang,
  • Andrew Thamboo

摘要

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory condition, often treated with oral corticosteroids (OCS). OCS overexposure can increase the risk of adverse effects, highlighting the need for better treatment strategies including timely biologic therapy use. This study explored OCS use patterns in patients with severe CRSwNP in Canada pre-biologic initiation.

Methods

This retrospective, real-world study used IQVIA’s Private Drug Plan (PDP) claims database to examine OCS use patterns 0–24 months pre-initiation of biologic therapy in patients with inferred CRSwNP in Canada (n = 747). Outcomes included OCS use patterns (proportions, claims per patient and by prescribing physician specialty, overexposure [≥ 1000 mg annually, prednisone-equivalent]), demographics, and stratified by comorbid asthma.

Results

Of 747 patients indexed from the PDP, 81.0% had ≥ 1 OCS claim(s), with a median (interquartile range [IQR]) of 3.0 (4.0) claims per patient. Median (IQR) total OCS dose over 24 months was 1020 (1420) mg; 41.5% of patients experienced OCS overexposure. OCS was primarily prescribed by general practitioners (35.9%) and otolaryngologists (32.8%). Patients had a median (IQR) age of 51 (18) years at index, 52.1% were male, and most were from Ontario (48.7%). OCS use was highest in patients with comorbid severe asthma.

Conclusions

This study highlights OCS overexposure in patients with CRSwNP pre-biologic initiation. Enhancing physician and patient awareness of appropriate OCS use and timely biologic initiation could reduce the risk of OCS-related adverse effects and improve CRSwNP management, benefiting long-term patient outcomes through shared decision-making.

Trial registration GSK study number 221872.